The genetic basis of hepatosplenic T-cell lymphoma Journal Article
| Authors: | McKinney, M.; Moffitt, A. B.; Gaulard, P.; Travert, M.; Leval, L. D.; Raffeld, A. N. M.; Jaffe, E. S.; Pittaluga, S.; Xi, L.; Heavican, T.; Iqbal, J.; Belhadj, K.; Delfau-Larue, M. H.; Fataccioli, V.; Czader, M. B.; Lossos, I. S.; Chapman-Fredricks, J. R.; Richards, K. L.; Fedoriw, Y.; Ondrejka, S. L.; Hsi, E. D.; Low, L.; Weisenburger, D.; Chan, W. C.; Mehta-Shah, N.; Horwitz, S.; Bernal-Mizrachi, L.; Flowers, C. R.; Beaven, A. W.; Parihar, M.; Baseggio, L.; Parrens, M.; Moreau, A.; Sujobert, P.; Pilichowska, M.; Evens, A. M.; Chadburn, A.; Au-Yeung, R. K. H.; Srivastava, G.; Choi, W. W. L.; Goodlad, J. R.; Aurer, I.; Basic-Kinda, S.; Gascoyne, R. D.; Davis, N. S.; Li, G.; Zhang, J.; Rajagopalan, D.; Reddy, A.; Love, C.; Levy, S.; Zhuang, Y.; Datta, J.; Dunson, D. B.; Davé, S. S. |
| Article Title: | The genetic basis of hepatosplenic T-cell lymphoma |
| Abstract: | Hepatosplenic T-cell lymphoma (HSTL) is a rare and lethal lymphoma; the genetic drivers of this disease are unknown. Through whole-exome sequencing of 68 HSTLs, we define recurrently mutated driver genes and copy-number alterations in the disease. Chromatin-modifying genes, including SETD2, INO80, and ARID1B, were commonly mutated in HSTL, affecting 62% of cases. HSTLs manifest frequent mutations in STAT5B (31%), STAT3 (9%), and PIK3CD (9%), for which there currently exist potential targeted therapies. In addition, we noted less frequent events in EZH2, KRAS, and TP53. SETD2 was the most frequently silenced gene in HSTL. We experimentally demonstrated that SETD2 acts as a tumor suppressor gene. In addition, we found that mutations in STAT5B and PIK3CD activate critical signaling pathways important to cell survival in HSTL. Our work thus defines the genetic landscape of HSTL and implicates gene mutations linked to HSTL pathogenesis and potential treatment targets. SIGNIFICANCE: We report the first systematic application of whole-exome sequencing to define the genetic basis of HSTL, a rare but lethal disease. Our work defines SETD2 as a tumor suppressor gene in HSTL and implicates genes including INO80 and PIK3CD in the disease. © 2017 American Association for Cancer Research. |
| Journal Title: | Cancer Discovery |
| Volume: | 7 |
| Issue: | 4 |
| ISSN: | 2159-8274 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2017-04-01 |
| Start Page: | 369 |
| End Page: | 379 |
| Language: | English |
| DOI: | 10.1158/2159-8290.cd-16-0330 |
| PROVIDER: | scopus |
| PMCID: | PMC5402251 |
| PUBMED: | 28122867 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 May 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work